Redeye: Genovis - Paradigm Play

Redeye lowers 2020 estimates in anticipation of a transition year for Genovis, a cutting-edge enzymes producer, but ups its long-term fair value following company visits and a review of the case. The emerging paradigm shift in bioprocessing plus solid fundamentals promises superior long-term growth. Falls in the stock in the challenging current environment would provide entry points to a compelling case whose best is yet to come. Genovis remains on Redeye’s Conviction Buy List.

Read more and download the Research Update: https://bit.ly/2XeGKnN

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/